Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
The epidermal growth factor receptor (EGFR) inhibitor class of agents have been reported to cause multiple cutaneous adverse events. These drug eruptions are thought by some to indicate a good prognosis. The authors report of a case of a psoriasiform scalp eruption simultaneously occurring with an acneiform or follicular rash in a single patient. To present knowledge, this is the first report of a psoriasiform eruption triggered by erlotinib. In addition, this case report demonstrates 2 completely distinct cutaneous morphologies occurring simultaneously with erlotinib therapy in a single patient.
Campbell
Tracy M
TM
Rush University Medical Center, Chicago, IL 60612, USA. tracy_campbell@rush.edu
Brown
Clarence W
CW
D017486:Acneiform Eruptions / Q000139:chemically induced; D000368:Aged; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D005499:Folliculitis / Q000139:chemically induced; D006801:Humans; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011565:Psoriasis / Q000139:chemically induced; D011799:Quinazolines / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride